BIOPROCESS VALIDATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Bioprocess Validation Market, By Test Type (Extractable Testing Services, Microbiological Testing Services, Physiochemical Testing Services, Integrity Testing Services, and Others (Compatibility Testing Services and Others)), By Process Component (Filter Elements, Media containers and bags, Freezing And Thawing Process Bags, Bioreactors, Transfer Systems, and Others (Mixing Systems and Others)), By End User (Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations, Academic and Research Institutes, and Other (Clinical Research Organizations and Others)), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023
Code : CMI6287
Pages :130
Formats :
Excel and PDF
Industry : Biotechnology

Bioprocess Validation Market Size and Trends

The Bioprocess Validation Market size is expected to reach US$ 460.9 million by 2030, from US$ 882.4 million in 2023, growing at a CAGR of 9.7% during the forecast period. Bioprocess validation refers to the process of demonstrating and ensuring that a biopharmaceutical manufacturing process consistently and reliably produces products that meet pre-determined quality standards and regulatory requirements. It involves validating critical process parameters, equipment, analytical testing methods, cleaning procedures, computer systems, and facilities. Bioprocess validation is crucial for ensuring drug safety, efficacy and quality. The key drivers boosting the bioprocess validation market growth include increasing R&D investments in pharmaceutical and biotechnology industries, growth of the biosimilars and biologics market, and favorable government regulations, among others.

The bioprocess validation market is segmented by test type, process type and end user and region. By test type, the market is segmented into extractable testing services, microbiological testing services, physiochemical testing services, integrity testing services and others. The test type segment accounted for the largest share in 2022. This is attributed to the high adoption of bioprocess instruments like bioreactors and chromatography systems by biopharmaceutical companies for validating their manufacturing processes.

Bioprocess Validation Market Trends:

Digitization and paperless validation: A significant trend is the move towards paperless validation leveraging automation, electronic logbooks and specialized IT infrastructure. Digital tools allow centralized management of validation lifecycle data in a secure and compliant manner. They also enhance accessibility to historical records and real-time information sharing between cross-functional teams to support continuous verification.
Adopting quality by design (QbD) principles: Biopharma firms are increasing the use of quality by design approaches for validation. QbD facilitates deeper process understanding for establishing control strategies and defining design spaces to ensure consistent quality. This science-based methodology with real-time release allows shifting validation from demonstrating compliance to continuous process verification.
Enhanced analytical testing: Advanced analytical tools like high-resolution mass spectrometry are gaining traction for characterizing biochemical properties, impurities and degradation products during validation. Additionally, analytical assay kits are being developed for specialized quantification of critical quality attributes like host cell DNA and residual proteins.
Combining regulatory compliance: Biopharmaceutical companies are adopting more integrated quality and validation strategies for their processes to allow combined compliance with multiple regulatory authorities. Unified validation protocols are being designed using quality risk management principles to meet requirements from FDA, EMA and ICH guidelines.